Below is a current listing of all clinical trials at Howard University Cancer Center. For more information, please contact Vickie Watkins at 202-806-7037.

A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer (B-38)
The purpose of this study is to compare three different regimens of chemotherapy in order to improve disease free survival in women with breast cancer.  Eligible women must have invasive breast cancer which is operable with positive axillary nodes.

Phase II Study of Capecitabine in Combination with Vinorelbine and Trastuzumab for the First- or Second-Line Treatment of HER2+ Metastatic Breast Cancer(N0337)
There is no established standard treatment option for women with metastatic HER2+ breast cancer whose disease has progressed despite receiving chemotherapy.  The goals of this study are to obtain maximum control of disease, symptoms, prevent serious complications and increase survival.

Comparing the Lozenge to the Patch for Smoking Cessation
The purpose of this study is to compare the nicotine patch to the nicotine lozenge for promoting continued abstinence from smoking.

Stress Management Therapy for Patients Undergoing Chemotherapy
The primary objective of this study is to determine if a self administered stress management intervention is effective in improving quality of life and decreasing psychological distress (anxiety and depression), in a single clinical setting.

A Phase III Trial of Irinotecan /5-FU/Leucovorin or Oxaliplatin /5-FULeucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum.(C80405)
The goal of this study is to determine if the addition of cetuximab to FOLFIRI or FOLFOX chemotherapy with and without bevacizumab prolongs survival compared to FOLFIRI or FOLFOX with bevacizumab in patients with untreated, advanced or metastatic colorectal cancer.

A Randomized Phase III study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (E5202)
The objective of the study is to demonstrate an improvement in 3-year disease-free survival for high-risk stage II colon cancer patients randomly assigned to 5-FU, leucovorin, oxaliplatin, versus 5- FU, leucovorin, oxaliplatin and bevacizumab.

A Phase IV, Randomized, Prospective , Multicenter Comparison of an Intermittent Schedule of Oxaliplatin (IO) Combined with 5-Fluorouracil, Leucovorin (FOLFOX)/Bevacizumab versus the Conventional (CO) Mode of Administration of FOLFOX/Bevacizumab +/-Neuroprophylaxis with Calcium /Magnesium for the Optimization of First-Line Therapy of Metastatic Colorectal Cancer (L_9444)
The primary rationale for this study is to develop an optimized schedule of administration of FOLFOX + bevacizumab that maximizes the efficacy and safety of this regimen when administered to patients with advanced colorectal cancer.

A Phase II Study of St. John’s Wort for the Treatment of Hot Flashes in Women with a History of Breast Cancer.

Cyclophosphamide and Doxorubicin (CA) (4 Vs 6 Cycles) Versus Paclitaxel (4 Vs 6 Cycles) Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes A 2X2 Factoral Phase III Randomized Study.

Program for the Assessment of Clinical Cancer Tests (PACCT-1); Trail Assigning Individualized Options for Treatment: The TAILORx Trial (PACCT-1)

A Phase III Trial of Ironotecan/5-FU, Leucovorian and Oxaliplatin Bevacizumab, or Cetuximab (C225), or with The Combination of Bevacizubab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum.

A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Flourouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer.

A Phase IV, Randomized, Prospective, Multicenter Comaprison of an Intermittent Schedule of Oxaliplatin (10) Combined with 5-Fluorouracil, Leucovorian (FOLFOX) Bevacizumab versus the Conventional (CO) Mode of Administration of FOLFOX/ Bevacizumab +/- Europrophylaxis with Calcium Magnesium for the Optimization of First-Line Therapy of Metastic Colon Cancer.

A Phase III Clinical Trial Comparing Osaliplatin, Capecitabine and Hepatic Arterial Infusion of Floxuridine to Oxaliplatin and Capacetibine in Patients with Resected or Ablated Liver Metastasesfrom Colorectal Cancer (C-09)

The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study.